These findings may thus help explain the differences observed between NC women and HC users in levels of CRP (Divani et al., 2015; Larsen et al., 2020; Masama et al., 2022; c.f. Caputi et al., 2022; Eagan et al., 2021; Larsen et al., 2020) and risk of developing inflammation-related conditions, such as depression and autoimmune disease. This evidence concerns the gene CRP and depressive symptom measurement.